Citigroup
TARO

Citigroup’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Citigroup’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,537
Closed -$65.1K – 5835
2024
Q1 		$65.1K Buy
1,537
+351
+30% +$14.8K ﹤0.01% 4498
2023
Q4 		$49.6K Buy
1,186
+1,171
+7,807% +$43.2K ﹤0.01% 4525
2023
Q3 		$566 Sell
15
-2,489
-99% -$93.4K ﹤0.01% 5186
2023
Q2 		$95K Buy
2,504
+2,441
+3,875% +$76.6K ﹤0.01% 4275
2023
Q1 		$1.53K Hold
63
– – ﹤0.01% 5119
2022
Q4 		$1.83K Hold
63
– – ﹤0.01% 5264
2022
Q3 		$2K Hold
63
– – ﹤0.01% 5556
2022
Q2 		$2K Hold
63
– – ﹤0.01% 5941
2022
Q1 		$3K Buy
+63
New +$2.94K ﹤0.01% 6007
2021
Q4 		– Sell
-4,473
Closed -$285K – 6142
2021
Q3 		$285K Buy
4,473
+3,900
+681% +$270K ﹤0.01% 3939
2021
Q2 		$41K Sell
573
-21,341
-97% -$1.57M ﹤0.01% 4918
2021
Q1 		$1.62M Buy
21,914
+614
+3% +$46.6K ﹤0.01% 2632
2020
Q4 		$1.56M Sell
21,300
-9,800
-32% -$630K ﹤0.01% 3083
2020
Q3 		$1.71M Sell
31,100
-200
-0.6% -$12.4K ﹤0.01% 2790
2020
Q2 		$2.08M Hold
31,300
– – ﹤0.01% 2766
2020
Q1 		$1.92M Buy
+31,300
New +$2.32M ﹤0.01% 2524
2019
Q4 		– Sell
-394
Closed -$30K – 7836
2019
Q3 		$30K Buy
+394
New +$32K ﹤0.01% 6479
2018
Q3 		– Sell
-29
Closed -$3K – 7898
2018
Q2 		$3K Buy
29
+20
+222% +$2.2K ﹤0.01% 7442
2018
Q1 		$1K Sell
9
-530
-98% -$53.7K ﹤0.01% 7479
2017
Q4 		$56K Sell
539
-4,052
-88% -$445K ﹤0.01% 6102
2017
Q3 		$517K Sell
4,591
-3,541
-44% -$385K ﹤0.01% 4088
2017
Q2 		$911K Sell
8,132
-968
-11% -$109K ﹤0.01% 3419
2017
Q1 		$1.06M Buy
9,100
+1,440
+19% +$159K ﹤0.01% 3150
2016
Q4 		$807K Buy
7,660
+4,010
+110% +$420K ﹤0.01% 3910
2016
Q3 		$403K Buy
3,650
+2,234
+158% +$296K ﹤0.01% 4096
2016
Q2 		$206K Sell
1,416
-1,141
-45% -$162K ﹤0.01% 4477
2016
Q1 		$366K Sell
2,557
-388
-13% -$55.1K ﹤0.01% 4479
2015
Q4 		$455K Sell
2,945
-1,629
-36% -$238K ﹤0.01% 3959
2015
Q3 		$653K Buy
4,574
+2,083
+84% +$291K ﹤0.01% 3486
2015
Q2 		$358K Buy
2,491
+2,476
+16,507% +$353K ﹤0.01% 3998
2015
Q1 		$2K Buy
+15
New +$2.31K ﹤0.01% 6965
2014
Q2 		– Sell
-227
Closed -$25K – 7356
2014
Q1 		$25K Buy
+227
New +$24.7K ﹤0.01% 5909

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Citigroup's TARO Position: Q2 2024 in Review

Citigroup sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 1,537 shares — an estimated $65.1K sold.

Citigroup first reported a position in TARO in Q1 2014 and held it in 32 quarters. The position peaked at $2.08M in Q2 2020. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • Citigroup reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • Citigroup sold 1,537 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $65.1K.
  • Citigroup first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2014 and held it in 32 quarters.
  • Citigroup's Taro Pharmaceutical Industries Ltd. position peaked at $2.08M in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.